Skip to content

Adamas Pharmaceuticals Inc

Delisted

CIK 1328143fmd_0156PNZJ49QJ4EVB7VAJZK93SWManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2012 to Sep 30, 2021, 36 periods

Latest annual · FY2020

Millions
Total revenues
74
Gross profit
72
Operating income
(44)
Net income
(57)
Free cash flow
(51)

Latest quarter · Q3 FY2021

Millions
Total revenues
26
Gross profit
25
Operating income
(6)
Net income
(20)
Free cash flow
(6)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2017 to FY2020
+407.1%
Revenue, 5 yearsFY2015 to FY2020
+107.9%
Net income, 5 yearsFY2015 to FY2020
n/m

Adamas Pharmaceuticals Inc financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2020FY2019ChangeSource
Revenue$74.5 million$54.6 million+36.3%10-K 2021-02-23 · proof
Gross profit$72.4 million$52.2 million+38.8%10-K 2021-02-23 · proof
Operating income-$44.2 million-$92.2 million10-K 2021-02-23 · proof
Net income-$57.4 million-$105.2 million10-K 2021-02-23 · proof
Cash from operating activities-$50.7 million-$80.8 million10-K 2021-02-23 · proof
Free cash flow-$50.7 million-$80.8 million10-K 2021-02-23 · proof
Total assets$120 million$162.2 million-26%10-K 2021-02-23 · proof
Total liabilities$170 million$163.1 million+4.3%10-K 2021-02-23 · proof
Cash and cash equivalents$71.7 million$65.8 million+8.9%10-K 2021-02-23 · proof
Total debt$130 million$127.7 million+1.8%10-K 2021-02-23 · proof
What was Adamas Pharmaceuticals Inc's revenue in fiscal 2020?
Adamas Pharmaceuticals Inc reported revenue of $74.5 million for fiscal 2020 (the year ended Dec 31, 2020), against $54.6 million the year before (+36.3%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What was Adamas Pharmaceuticals Inc's gross profit in fiscal 2020?
Adamas Pharmaceuticals Inc reported gross profit of $72.4 million for fiscal 2020 (the year ended Dec 31, 2020), against $52.2 million the year before (+38.8%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What was Adamas Pharmaceuticals Inc's operating income in fiscal 2020?
Adamas Pharmaceuticals Inc reported operating income of -$44.2 million for fiscal 2020 (the year ended Dec 31, 2020), against -$92.2 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What was Adamas Pharmaceuticals Inc's net income in fiscal 2020?
Adamas Pharmaceuticals Inc reported net income of -$57.4 million for fiscal 2020 (the year ended Dec 31, 2020), against -$105.2 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What was Adamas Pharmaceuticals Inc's cash from operating activities in fiscal 2020?
Adamas Pharmaceuticals Inc reported cash from operating activities of -$50.7 million for fiscal 2020 (the year ended Dec 31, 2020), against -$80.8 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What was Adamas Pharmaceuticals Inc's free cash flow in fiscal 2020?
Adamas Pharmaceuticals Inc reported free cash flow of -$50.7 million for fiscal 2020 (the year ended Dec 31, 2020), against -$80.8 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What are Adamas Pharmaceuticals Inc's total assets?
As of Dec 31, 2020, Adamas Pharmaceuticals Inc reported total assets of $120 million, against $162.2 million a year earlier (-26%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What are Adamas Pharmaceuticals Inc's total liabilities?
As of Dec 31, 2020, Adamas Pharmaceuticals Inc reported total liabilities of $170 million, against $163.1 million a year earlier (+4.3%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What are Adamas Pharmaceuticals Inc's cash and cash equivalents?
As of Dec 31, 2020, Adamas Pharmaceuticals Inc reported cash and cash equivalents of $71.7 million, against $65.8 million a year earlier (+8.9%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
What is Adamas Pharmaceuticals Inc's total debt?
As of Dec 31, 2020, Adamas Pharmaceuticals Inc reported total debt of $130 million, against $127.7 million a year earlier (+1.8%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1328143&period_type=annual&limit=5"

Information only, not investment advice.